新辅助免疫化疗在可切除非小细胞肺癌中的研究进展

李 　博1, 姜　 军*2
1、青海大学
2、青海大学附属医院

摘要


非小细胞肺癌（non small cell lung cancer，NSCLC）是肺癌中最为常见的一种亚型，其发病率和死亡率均居
高不下，严重威胁着人类的健康和生命。对于早期和局部晚期的NSCLC，手术仍是治愈性治疗的基石。尽管积极进
行新辅助化疗或辅助化疗，5年生存率仅提高5%。免疫化疗作为一种新兴治疗策略，改变了可切除NSCLC在新辅助
治疗中进展停滞不前的状况，多个研究已经证明新辅助免疫化疗在可切除NSCLC中的疗效和安全性。本综述讨论了
新辅助免疫化疗在可切除NSCLC的作用机制及研究现状，并探讨了未来发展趋势。

关键词


非小细胞肺癌；围手术期；新辅助免疫化疗；免疫检查点抑制剂

全文:

PDF


参考


[1]SIEGEL R L, MILLER K D, WAGLE N S, et al.

Cancer statistics, 2023 [J]. CA: a cancer journal for clinicians,

2023, 73(1): 17-48.

[2]GOLDSTRAW P, CHANSKY K, CROWLEY J,

et al. The IASLC Lung Cancer Staging Project: Proposals for

Revision of the TNM Stage Groupings in the Forthcoming

(Eighth) Edition of the TNM Classification for Lung Cancer

[J]. Journal of thoracic oncology : official publication of the

International Association for the Study of Lung Cancer, 2016,

11(1): 39-51.

[3]DALY M E, SINGH N, ISMAILA N, et al.

Management of Stage III Non-Small-Cell Lung Cancer:

ASCO Guideline [J]. Journal of clinical oncology : official

journal of the American Society of Clinical Oncology, 2022,

40(12): 1356-84.

[4]DUMA N, SANTANA-DAVILA R, MOLINA J

R. Non-Small Cell Lung Cancer: Epidemiology, Screening,

Diagnosis, and Treatment [J]. Mayo Clinic proceedings, 2019,

94(8): 1623-40.

[5]BAGCHI S, YUAN R, ENGLEMAN E G. Immune

Checkpoint Inhibitors for the Treatment of Cancer: Clinical

Impact and Mechanisms of Response and Resistance [J].

Annual review of pathology, 2021, 16: 223-49.

[6]MENG L F, HUANG J F, LUO P H, et al. The

efficacy and safety of immune checkpoint inhibitor plus

chemotherapy in patients with advanced non-small-cell lung

cancer: a meta-analysis [J]. Investigational new drugs, 2022,

40(4): 810-7.

[7]LIU L, BAI H, WANG C, et al. Efficacy and Safety

of First-Line Immunotherapy Combinations for Advanced

NSCLC: A Systematic Review and Network Meta-Analysis

[J]. Journal of thoracic oncology : official publication of the

International Association for the Study of Lung Cancer, 2021,

16(7): 1099-117.

[ 8 ] R E C K M , R O D R í G U E Z - A B R E U D ,

ROBINSON A G, et al. Five-Year Outcomes With

Pembrolizumab Versus Chemotherapy for Metastatic NonSmall-Cell Lung Cancer With PD-L1 Tumor Proportion

Score ≥ 50 [J]. Journal of clinical oncology : official journal

of the American Society of Clinical Oncology, 2021, 39(21):

2339-49.

[9]CASCONE T, LEUNG C H, WEISSFERDT A,

et al. Neoadjuvant chemotherapy plus nivolumab with or

without ipilimumab in operable non-small cell lung cancer:

the phase 2 platform NEOSTAR trial [J]. Nature medicine,

2023, 29(3): 593-604.

[10]HOU X, SHI X, LUO J. Efficacy and safety

of camrelizumab (a PD-1 inhibitor) combined with

chemotherapy as a neoadjuvant regimen in patients with

locally advanced non-small cell lung cancer [J]. Oncology

letters, 2022, 24(1): 215.

[11]ZHAO D, XU L, WU J, et al. Comparison of

perioperative outcomes among non-small cell lung cancer

patients with neoadjuvant immune checkpoint inhibitor plus

chemotherapy, EGFR-TKI, and chemotherapy alone: a realworld evidence study [J]. Translational lung cancer research,

2022, 11(7): 1468-78.

[12]CHAFT J E, RIMNER A, WEDER W, et al.

Evolution of systemic therapy for stages I-III non-metastatic

non-small-cell lung cancer [J]. Nature reviews Clinical

oncology, 2021, 18(9): 547-57.

[13]DESAI A P, ADASHEK J J, REUSS J E, et al.

Perioperative Immune Checkpoint Inhibition in EarlyStage Non-Small Cell Lung Cancer: A Review [J]. JAMA

oncology, 2023, 9(1): 135-42.

[14]UPRETY D, MANDREKAR S J, WIGLE D, et al.

Neoadjuvant Immunotherapy for NSCLC: Current Concepts

and Future Approaches [J]. Journal of thoracic oncology :

official publication of the International Association for the

Study of Lung Cancer, 2020, 15(8): 1281-97.

[15]FORDE P M, SPICER J, LU S, et al. Neoadjuvant

Nivolumab plus Chemotherapy in Resectable Lung Cancer [J].

The New England journal of medicine, 2022, 386(21): 1973-

85.

[16]HEYMACH J V, HARPOLE D, MITSUDOMI T,

et al. Perioperative Durvalumab for Resectable Non-SmallCell Lung Cancer [J]. The New England journal of medicine,

2023, 389(18): 1672-84.

[17]SPRING L M, FELL G, ARFE A, et al. Pathologic

Complete Response after Neoadjuvant Chemotherapy

and Impact on Breast Cancer Recurrence and Survival: A

Comprehensive Meta-analysis [J]. Clinical cancer research

: an official journal of the American Association for Cancer

Research, 2020, 26(12): 2838-48.

[18]CORTAZAR P, ZHANG L, UNTCH M, et al.

Pathological complete response and long-term clinical benefit

in breast cancer: the CTNeoBC pooled analysis [J]. Lancet

(London, England), 2014, 384(9938): 164-72.

[19]MOUILLET G, MONNET E, MILLERON

B, et al. Pathologic complete response to preoperative

chemotherapy predicts cure in early-stage non-small-cell

lung cancer: combined analysis of two IFCT randomized trials

[J]. Journal of thoracic oncology : official publication of the

International Association for the Study of Lung Cancer, 2012,

7(5): 841-9.

[20]CHEN Y, QIN J, WU Y, et al. Does major

pathological response after neoadjuvant Immunotherapy in

resectable nonsmall-cell lung cancers predict prognosis? A

systematic review and meta-analysis [J]. International journal

of surgery (London, England), 2023, 109(9): 2794-807.

[21]AKINBORO O, DREZNER N, AMATYA A, et

al. US Food and Drug Administration Approval Summary:

Nivolumab Plus Platinum-Doublet Chemotherapy for the

Neoadjuvant Treatment of Patients With Resectable NonSmall-Cell Lung Cancer [J]. Journal of clinical oncology :

official journal of the American Society of Clinical Oncology,

2023, 41(17): 3249-59.

[22]PROVENCIO M, NADAL E, GONZáLEZLARRIBA J L, et al. Perioperative Nivolumab and

Chemotherapy in Stage III Non-Small-Cell Lung Cancer [J].

The New England journal of medicine, 2023, 389(6): 504-13.

[23]CASCONE T, AWAD M M, SPICER J D, et al.

Perioperative Nivolumab in Resectable Lung Cancer [J]. The

New England journal of medicine, 2024, 390(19): 1756-69.

[24]WAKELEE H, LIBERMAN M, KATO T, et al.

Perioperative Pembrolizumab for Early-Stage Non-SmallCell Lung Cancer [J]. The New England journal of medicine,

2023, 389(6): 491-503.

[25]LU S, ZHANG W, WU L, et al. Perioperative

Toripalimab Plus Chemotherapy for Patients With Resectable

Non-Small Cell Lung Cancer: The Neotorch Randomized

Clinical Trial [J]. Jama, 2024, 331(3): 201-11.

[26]YUE D, WANG W, LIU H, et al. VP1-2024:

RATIONALE-315: Event-free survival (EFS) and

overall survival (OS) of neoadjuvant tislelizumab (TIS) plus

chemotherapy (CT) with adjuvant TIS in resectable nonsmall cell lung cancer (NSCLC) [J]. Annals of Oncology,

2024, 35(3): 332-3.

[27]MEI T, ZHOU Q, GONG Y. Comparison of the

Efficacy and Safety of Perioperative Immunochemotherapeutic

Strategies for Resectable Non-small Cell Lung Cancer: a

Systematic Review and Network Meta-analysis [J]. Clinical

oncology (Royal College of Radiologists (Great Britain)),

2024, 36(2): 107-18.

[28]ZHOU Y, LI A, YU H, et al. NeoadjuvantAdjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors

for Patients With Resectable NSCLC: An Indirect MetaAnalysis [J]. JAMA network open, 2024, 7(3): e241285.

[29]NI J, HUANG M, ZHANG L, et al. Clinical

recommendations for perioperative immunotherapy-induced

adverse events in patients with non-small cell lung cancer [J].

Thoracic cancer, 2021, 12(9): 1469-88.

[30]OWEN C N, BAI X, QUAH T, et al. Delayed

immune-related adverse events with anti-PD-1-based

immunotherapy in melanoma [J]. Annals of oncology : official

journal of the European Society for Medical Oncology, 2021,

32(7): 917-25.

[31]AHERN E, SOLOMON B J, HUI R, et al.

Neoadjuvant immunotherapy for non-small cell lung

cancer: right drugs, right patient, right time? [J]. Journal for

immunotherapy of cancer, 2021, 9(6).

[32]DENG H, LIANG H, CHEN J, et al. Preoperative

immunochemotherapy for locally advanced non-small cell

lung cancer: an analysis of the clinical outcomes, optimal

number of cycles, and peripheral immune markers [J].

Translational lung cancer research, 2022, 11(12): 2364-81.

[33]SHAO M, YAO J, WANG Y, et al. Two vs three

cycles of neoadjuvant sintilimab plus chemotherapy for

resectable non-small-cell lung cancer: neoSCORE trial [J].

Signal transduction and targeted therapy, 2023, 8(1): 146.

[34]TIAN W, NIU L, WANG Z, et al. Costeffectiveness of neoadjuvant pembrolizumab plus

chemotherapy with adjuvant pembrolizumab for early-stage

non-small cell lung cancer in the United States [J]. Frontiers

in immunology, 2023, 14: 1268070.

[35]GADGEEL S, RODRíGUEZ-ABREU D,

SPERANZA G, et al. Updated Analysis From KEYNOTE-

189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum

for Previously Untreated Metastatic Nonsquamous NonSmall-Cell Lung Cancer [J]. Journal of clinical oncology :

official journal of the American Society of Clinical Oncology,

2020, 38(14): 1505-17.

[36]ADDEO A, FRIEDLAENDER A, BANNA G L, et

al. TMB or not TMB as a biomarker: That is the question [J].

Critical reviews in oncology/hematology, 2021, 163: 103374.

[37]SESMA A, PARDO J, CRUELLAS M, et al.

From Tumor Mutational Burden to Blood T Cell Receptor:

Looking for the Best Predictive Biomarker in Lung Cancer

Treated with Immunotherapy [J]. Cancers, 2020, 12(10).

[38]JEE J, LEBOW E S, YEH R, et al. Overall survival

with circulating tumor DNA-guided therapy in advanced

non-small-cell lung cancer [J]. Nature medicine, 2022,

28(11): 2353-63.

[39]HEITZER E, VAN DEN BROEK D, DENIS M

G, et al. Recommendations for a practical implementation of

circulating tumor DNA mutation testing in metastatic nonsmall-cell lung cancer [J]. ESMO open, 2022, 7(2): 100399.


Refbacks

  • 当前没有refback。